GC Medical Science녹십자엠에스

GC Medical Science returned to a small operating profit on a trailing basis, but still reports a net loss and carries rising debt.

The company sells diagnostic reagents, blood glucose monitoring products and hemodialysis fluid in Korea. On a trailing twelve-month basis to H1 2026 it had revenue of ₩102B... more precisely ₩102.2B, an operating profit of about ₩2.4B and a net loss of about ₩2.2B. The shares closed at ₩3,250 on 2026-10-26, well below the 52-week high of ₩6,660.

What stands out

• Trailing revenue is about ₩102.2B, a little below the ₩108.4B reported for 2025, while the trailing operating margin is 2.3%.
• Trailing net income is a loss of about ₩2.2B, compared with net profit of ₩3.7B in 2025, so the business is not yet profitable after finance and other costs.
• Borrowings are about ₩8.7B against cash of only about ₩0.3B, and liabilities are 72.9% of equity.
• Trailing free cash flow is about ₩7.3B, which is positive despite the net loss.
• News in October 2026 covers a tie-up with China's Yuwell to pursue domestic introduction of continuous glucose monitors; the data does not give financial terms or timing.
• Foreign ownership fell from 3.2% to 0.5% over about 60 days, while retail investors were net buyers over the last 20 days.

What to watch

• The next quarterly or half-year filings, to see whether operating profit turns into net profit.
• Progress on the Yuwell continuous glucose monitor introduction, which the data does not yet quantify.
• Debt levels against thin cash, and any further warrant or new-share filings that could dilute holders.